Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Role of Resmetirom, a Liver-Directed, Thyroid Hormone Receptor Beta-Selective Agonist, in Managing Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis
Deep Dutta, A B Kamrul-Hasan, E Mondal, et al.
Endocrine Practice (2024) Vol. 30, Iss. 7, pp. 631-638
Closed Access | Times Cited: 11

Showing 11 citing articles:

A New Hope for the Patients of Non‐Alcoholic Steatohepatitis: FDA Gives Green Signal for Resmetirom Use
Abdul Haseeb Hasan, M. Abid, Мuhammad Abid, et al.
Health Science Reports (2025) Vol. 8, Iss. 1
Open Access | Times Cited: 2
Thyromimetics and MASLD: Unveiling the Novel Molecules Beyond Resmetirom
Devaraj Ezhilarasan
Journal of Gastroenterology and Hepatology (2025)
Closed Access | Times Cited: 1
Cardiovascular-Liver-Metabolic Health: Recommendations in Screening, Diagnosis, and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease in Cardiovascular Disease via Modified Delphi Approach
Nicholas Chew, Anurag Mehta, Rachel Sze Jen Goh, et al.
Circulation (2024) Vol. 151, Iss. 1, pp. 98-119
Closed Access | Times Cited: 7
Emerging mechanisms of non-alcoholic steatohepatitis and novel drug therapies
Hao Chen, Yang Zhou, Haiping Hao, et al.
Chinese Journal of Natural Medicines (2024) Vol. 22, Iss. 8, pp. 724-745
Closed Access | Times Cited: 5
Unlocking the potential of THR-β agonist therapies: resmetirom’s chemistry, biology, and patent insights
K. K. Dahiya, Mahesh Palkar, Sanjay Sharma
Naunyn-Schmiedeberg s Archives of Pharmacology (2025)
Closed Access
The Drug Update
Angelo Marino, Jenna D. Theroux, Evan S. Drake, et al.
The Nurse Practitioner (2025) Vol. 50, Iss. 2, pp. 27-40
Open Access
Resmetirom for Moderate to Advanced Liver Fibrosis
Devada Singh-Franco, Melissa Santibañez, Huy Quang Pham, et al.
The Journal for Nurse Practitioners (2025), pp. 105330-105330
Closed Access
Resmetirom: Breakthrough therapeutic approach for metabolic dysfunction-associated steatohepatitis
A. Saeed, Kuldeep Dalpat, Muzammil Saeed
Liver Research (2024) Vol. 8, Iss. 3, pp. 193-194
Open Access | Times Cited: 1
Beyond resmetirom approval for NAFLD: what has to be done?
Devaraj Ezhilarasan
Drug Discovery Today (2024), pp. 104185-104185
Closed Access | Times Cited: 1
Resmetirom: New Drug, Familiar Challenges?
Timothy W. Bodnar, Heather McCurdy
Endocrine Practice (2024) Vol. 30, Iss. 8, pp. 768-769
Closed Access
Biochemical basis and therapeutic potential of mitochondrial uncoupling in cardiometabolic syndrome
Bernardo Gindri dos Santos, Niki F. Brisnovali, Leigh Goedeke
Biochemical Journal (2024) Vol. 481, Iss. 23, pp. 1831-1854
Closed Access
Page 1

Scroll to top